FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740828884> ?p ?o ?g. }

• W2740828884 abstract "Estrogen receptor positive (ER+) breast cancer is treated with endocrine therapy but intrinsic resistance occurs in ~1/3 of patients and acquired resistance in ~1/5 of the remainder. While many resistance mechanisms have been explored, therapeutic strategies to overcome resistance in the clinical setting have seen mixed outcomes, and appear most effective in the acquired resistance setting. Understanding mechanisms of resistance and finding therapeutic strategies to target them, therefore, remain important challenges facing breast cancer researchers. In this study we systematically examine the role of DNA damage repair defects in inducing endocrine therapy resistance, a relatively understudied question of recent interest. We use in silico analysis of clinical datasets, in vitro experiments evaluating endocrine therapy resistance in response to DDR dysregulation in multiple breast cancer celllines, and in vivo validation using cellline xenograft and patient-derived xenograft models. We also use gene expression microarrays and RPPA data from cell lines, patient-derived xenografts and primary ER+ breast tumors to uncover therapeutic options that are validated in vitro and in vivo and corroborated by clinical trial data. The results of this study uncover an intriguing link between mismatch repair (MMR) deficiency, specifically of the MutL complex (MLH1/3, PMS1/2), and poor prognosis in ER+ disease. We find a direct role for MutL loss in endocrine therapy resistance in vitro and in vivo by knocking down multiple MutL genes using CRISPR and stable shRNA approaches validated using standard rescue experiments. We identify the underlying mechanism: MutL deficiency in ER+ breast cancer abrogates Chk2-mediated feedback inhibition of CDK4/6 that appears necessary for endocrine therapy responsiveness. Consequently, pharmacological targeting of CDK4/6 in vitro and in vivo significantly inhibits growth of endocrine therapy resistant MutL-deficient ER+ breast cancer cells. These results are corroborated by data from a neoadjuvant clinical trial demonstrating that cell cycle regulation of MutL-mutant tumors tends to be estrogen-independent but sensitive to CDK4/6 inhibitors. The results of this study provide important biological and clinically relevant insights. 1) MMR deficiency is unexpectedly causal to intrinsic endocrine therapy resistance 2) This causal effect appears to be mediated by abrogation of cell cycle checkpoint activation in response to endocrine therapy 3) MMR deficiency in a subset of ER+ tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy resistant tumors. While there are currently no biomarkers to guide the use of CDK4/6 inhibitors for ER+ breast cancer, markers of MMR dysregulation could identify patients in whom CDK4/6 inhibition should be used to prevent disease recurrence. Citation Format: Svasti Haricharan, Jacob Schmelz, Cheryl Schmidt, Purba Singh, Kimberly R. Holloway, Meenakshi Anurag, Shunqiang Li, Shyam M. Kavuri, Shixia Huang, Dean P. Edwards, Vera Suman, Kelly Hunt, John A. Olson, Jeremy Hoog, Cynthia X. Ma, Matthew N. Bainbridge, Matthew J. Ellis. Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 489. doi:10.1158/1538-7445.AM2017-489" @default.
• W2740828884 created "2017-08-08" @default.
• W2740828884 creator A5007718798 @default.
• W2740828884 creator A5008295147 @default.
• W2740828884 creator A5009199118 @default.
• W2740828884 creator A5009670182 @default.
• W2740828884 creator A5017411324 @default.
• W2740828884 creator A5017653916 @default.
• W2740828884 creator A5018447438 @default.
• W2740828884 creator A5024724100 @default.
• W2740828884 creator A5028471851 @default.
• W2740828884 creator A5030664006 @default.
• W2740828884 creator A5034234418 @default.
• W2740828884 creator A5041647239 @default.
• W2740828884 creator A5057135409 @default.
• W2740828884 creator A5072416022 @default.
• W2740828884 creator A5082661564 @default.
• W2740828884 creator A5083507934 @default.
• W2740828884 creator A5091612898 @default.
• W2740828884 date "2017-07-01" @default.
• W2740828884 modified "2023-09-27" @default.
• W2740828884 title "Abstract 489: Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer" @default.
• W2740828884 doi "https://doi.org/10.1158/1538-7445.am2017-489" @default.
• W2740828884 hasPublicationYear "2017" @default.
• W2740828884 type Work @default.
• W2740828884 sameAs 2740828884 @default.
• W2740828884 citedByCount "0" @default.
• W2740828884 crossrefType "proceedings-article" @default.
• W2740828884 hasAuthorship W2740828884A5007718798 @default.
• W2740828884 hasAuthorship W2740828884A5008295147 @default.
• W2740828884 hasAuthorship W2740828884A5009199118 @default.
• W2740828884 hasAuthorship W2740828884A5009670182 @default.
• W2740828884 hasAuthorship W2740828884A5017411324 @default.
• W2740828884 hasAuthorship W2740828884A5017653916 @default.
• W2740828884 hasAuthorship W2740828884A5018447438 @default.
• W2740828884 hasAuthorship W2740828884A5024724100 @default.
• W2740828884 hasAuthorship W2740828884A5028471851 @default.
• W2740828884 hasAuthorship W2740828884A5030664006 @default.
• W2740828884 hasAuthorship W2740828884A5034234418 @default.
• W2740828884 hasAuthorship W2740828884A5041647239 @default.
• W2740828884 hasAuthorship W2740828884A5057135409 @default.
• W2740828884 hasAuthorship W2740828884A5072416022 @default.
• W2740828884 hasAuthorship W2740828884A5082661564 @default.
• W2740828884 hasAuthorship W2740828884A5083507934 @default.
• W2740828884 hasAuthorship W2740828884A5091612898 @default.
• W2740828884 hasConcept C104317684 @default.
• W2740828884 hasConcept C111425858 @default.
• W2740828884 hasConcept C121608353 @default.
• W2740828884 hasConcept C126322002 @default.
• W2740828884 hasConcept C134935766 @default.
• W2740828884 hasConcept C143998085 @default.
• W2740828884 hasConcept C207001950 @default.
• W2740828884 hasConcept C2777176818 @default.
• W2740828884 hasConcept C502942594 @default.
• W2740828884 hasConcept C526805850 @default.
• W2740828884 hasConcept C530470458 @default.
• W2740828884 hasConcept C54355233 @default.
• W2740828884 hasConcept C60644358 @default.
• W2740828884 hasConcept C60748783 @default.
• W2740828884 hasConcept C71924100 @default.
• W2740828884 hasConcept C84606932 @default.
• W2740828884 hasConcept C86803240 @default.
• W2740828884 hasConceptScore W2740828884C104317684 @default.
• W2740828884 hasConceptScore W2740828884C111425858 @default.
• W2740828884 hasConceptScore W2740828884C121608353 @default.
• W2740828884 hasConceptScore W2740828884C126322002 @default.
• W2740828884 hasConceptScore W2740828884C134935766 @default.
• W2740828884 hasConceptScore W2740828884C143998085 @default.
• W2740828884 hasConceptScore W2740828884C207001950 @default.
• W2740828884 hasConceptScore W2740828884C2777176818 @default.
• W2740828884 hasConceptScore W2740828884C502942594 @default.
• W2740828884 hasConceptScore W2740828884C526805850 @default.
• W2740828884 hasConceptScore W2740828884C530470458 @default.
• W2740828884 hasConceptScore W2740828884C54355233 @default.
• W2740828884 hasConceptScore W2740828884C60644358 @default.
• W2740828884 hasConceptScore W2740828884C60748783 @default.
• W2740828884 hasConceptScore W2740828884C71924100 @default.
• W2740828884 hasConceptScore W2740828884C84606932 @default.
• W2740828884 hasConceptScore W2740828884C86803240 @default.
• W2740828884 hasLocation W27408288841 @default.
• W2740828884 hasOpenAccess W2740828884 @default.
• W2740828884 hasPrimaryLocation W27408288841 @default.
• W2740828884 hasRelatedWork W1562816255 @default.
• W2740828884 hasRelatedWork W1986348049 @default.
• W2740828884 hasRelatedWork W2067755608 @default.
• W2740828884 hasRelatedWork W2087291737 @default.
• W2740828884 hasRelatedWork W2087897920 @default.
• W2740828884 hasRelatedWork W2102803803 @default.
• W2740828884 hasRelatedWork W2173030945 @default.
• W2740828884 hasRelatedWork W2431682936 @default.
• W2740828884 hasRelatedWork W2594322297 @default.
• W2740828884 hasRelatedWork W2742281710 @default.
• W2740828884 hasRelatedWork W2789357724 @default.
• W2740828884 hasRelatedWork W2810962597 @default.
• W2740828884 hasRelatedWork W2955947333 @default.
• W2740828884 hasRelatedWork W3006674748 @default.
• W2740828884 hasRelatedWork W3013749746 @default.
• W2740828884 hasRelatedWork W3013956661 @default.
• W2740828884 hasRelatedWork W3024684302 @default.
• W2740828884 hasRelatedWork W3087060191 @default.

• next